E uiga i le kanesa / togafitiga / faʻataʻitaʻi-faʻafitauli / faʻamaʻi / paʻu-kanesa / togafitiga
Togafitiga Togafitiga Togafitiga mo le kanesa o le paʻu e le Melanoma
Togafitiga faʻafomaʻi o suʻesuʻega suʻesuʻega e aʻafia ai tagata. O faʻataʻitaʻiga faʻafomaʻi i luga o lenei lisi e mo le le-melanoma paʻu kanesa togafitiga. O faʻataʻitaʻiga uma i luga o le lisi e lagolagoina e le NCI.
O faʻamatalaga taua a le NCI e uiga ile faʻataʻitaʻi ile falemaʻi o loʻo faʻamatalaina ai ituaiga ma vaega o faʻataʻitaʻiga ma faʻafefea ona faʻatinoina. Togafitiga faʻafomaʻi e vaʻai i ni auala fou e puipuia ai, iloa ai, pe togafitia ai faʻamaʻi. Atonu e te manaʻo e mafaufau e uiga i le auai i le faʻataʻitaʻiina o togafitiga. Talanoa i lau fomaʻi mo se fesoasoani i le filifiliga pe o se tasi e talafeagai mo oe.
Tofotofoga 1-25 o le 118 1 2 3 4 5 Le isi>
Faʻataʻitaʻia togafitiga faʻataʻitaʻia e Genetic Suʻesuʻega i le togafitia o tagata mamaʻi ma le maualuga o le Refractory Solid Tumors, Lymphomas, poʻo le tele Myeloma (Le MATCH Screening Trial)
Lenei vaega II MATCH faʻataʻitaʻiga suʻesuʻega pe faʻafefea ona lelei togafitiga e faʻatonutonuina e le suʻesuʻeina o gaioiga galue i tagata mamaʻi ma tuma poʻo ni lymphomas na alualu i luma mulimuli i le le itiiti ifo ma le tasi le laina o togafitiga masani pe leai foi se maliega i luga o togafitiga auala. O suʻesuʻega faʻafuaseʻi e vaʻai i le vaega o le tupuʻaga (genes) o sela tuma o tagata mamaʻi. Tagata mamaʻi e iai faʻasologa masani (e pei ole fesuiaʻiga, faʻalautelega, poʻo le fesuiaʻiga) e ono sili atu ona aoga i ai togafitiga e faʻatatau i le tulaga masani o latou tino. Ole faʻailoaina muamua ole gaʻoa ole gafa e ono fesoasoani ile fomaʻi e fuafua lelei togafitiga mo tagata mamaʻi e iai le tuma tuma, lymphomas, poʻo le tele myeloma.
Nofoaga: 1189 nofoaga
Nivolumab i le maeʻa ai o le tuʻufaʻatasia o togafitiga masani i le togafitia o tagata mamaʻi ma le tulaga lamatia maualuga II-IIIB Anal Cancer
Lenei randomized vaega II falemaʻi suʻesuʻega suʻesuʻega pe o le a le lelei o le nivolumab pe a maeʻa tuʻufaʻatasia metality togafitiga e galue ai i le togafitia o tagata gasegase maualuga tulaga lamatia II-IIIB anal kanesa. Immunotherapy ma monoclonal antibodies, pei o le nivolumab, e ono fesoasoani i le tino o le tino i osofaʻiga o le kanesa, ma ono faʻalavelave ai ile mafai o sela tuma e tutupu ma sosolo.
Nofoaga: 745 nofoaga
Pembrolizumab Faʻatusatusa i le Tulaga masani o Tausiga mataituina i le togafitia o tagata mamaʻi ma le maeʻa toe suʻesuʻeina Vaega I-III Merkel sela Kanesa
Lenei vaega III faʻataʻitaʻiga suʻesuʻega pe faʻafefea ona aoga le pembrolizumab pe a faʻatusatusa i le tulaga masani o le vaʻaia o tausiga i le togafitia o tagata mamaʻi i le tulaga I-III Merkel cell kanesa ua matua aveʻesea e le taotoga (toe maua). Immunotherapy ma monoclonal antibodies, pei o le pembrolizumab, ono fesoasoani i le tino o le tino puipuia osofaia le kanesa, ma ono faʻalavelave i le mafai o tumo sela e tupu ma salalau.
Nofoaga: 286 nofoaga
Avelumab ma pe leai Cetuximab i le togafitia o tagata mamaʻi ma le maualuga o le paʻu Squamous sela kanesa
Lenei vaega II suʻesuʻega suʻesuʻe pe o le avelumab ma le leai o cetuximab galue i le togafitia o tagata mamaʻi ma le paʻu sela sela sela ua salalau atu i isi nofoaga o le tino (alualu i luma). Immunotherapy ma monoclonal antibodies, pei o le avelumab ma cetuximab, e ono fesoasoani i le tino o le tino i osofaʻiga o le kanesa, ma ono faʻalavelave ai ile mafai o sela tuma e tutupu ma sosolo.
Nofoaga: 277 nofoaga
Pembrolizumab ma pe leai Stereotactic Tino Radiation Togafitiga i le togafitia o tagata mamaʻi ma Advanced po o Metastatic Merkel Cell Kanesa
O lenei faʻataʻitaʻiga laasaga II faʻataʻitaʻiga suʻesuʻega pe faʻafefea ona lelei le pandrolizumab ma le leai o le stereotactic body radiation therapy e galue ai i le togafitia o tagata mamaʻi ma le kanesa sela o Merkel ua salalau atu i isi nofoaga i le tino. Immunotherapy ma monoclonal antibodies, pei o le pembrolizumab, ono fesoasoani i le tino o le tino puipuia osofaia le kanesa, ma ono faʻalavelave i le mafai o tumo sela e tupu ma salalau. O le Stereotactic body radiation therapy e faʻaaoga ai meafaigaluega faʻapitoa e faʻatulagaina ai se tagata maʻi ma tuʻuina atu le radiation i tumors ma le maualuga atoatoa. Lenei metotia mafai fasiotia fasiotia sela sela ma le itiiti ifo tui i luga o se puʻupuʻu vaitaimi ma mafua ai laʻititi faʻaleagaina o masani aano. Le mauaina o le pembrolizumab ma le stereotactic body radiation therapy atonu e sili atu le aoga ile togafitia o tagata mamaʻi ile Merkel cell cancer.
Nofoaga: 246 nofoaga
Malosiaga ma le Saogalemuina Suʻesuʻega o Tisotumab Vedotin mo Tagata Maʻi Ma Tumors Mautu
Lenei faamasinoga o le a suesueina tisotumab vedotin e iloa ai pe o se lelei togafitiga mo nisi mautu tuma ma o a itu aafiaga (le manaʻomia aafiaga) ono tupu. O le togafitiga o le a tuuina atu i tagata gasegase tai tolu vaiaso.
Nofoaga: 12 nofoaga
PD-1 i Tagata Maʻi Ma le Maualuga Basal Cell Carcinoma O Ai na Faʻaalia le alualu i luma o Faʻamaʻi i luga o Hedgehog Pathway Inhibitor Therapy, pe na le faʻapalepale i le muamua Hedgehog Pathway Inhibitor Therapy.
O le autu autu o le iloiloina o le aotelega tali fua faatatau (ORR) mo metastatic Basal Cell Carcinoma (BCC) (vaega 1) ma mo le le mafaagaloina lotoifale BCC (kulupu 2) pe a togafitia ma REGN2810 o se monotherapy
Nofoaga: 15 nofoaga
Vaega II Suesuega o Tipifarnib i le Squamous Head ma le Kanesa o le ua Ma le HRAS Mutations
Vaega II suʻesuʻega e suʻesuʻe ai le gaioiga a le antitumor e tusa ai ma le fua faatatau o le tali atu (ORR) o le tipifarnib i mataupu o loʻo i ai ni tuma maualuluga o loʻo tauʻavea le HRAS ma e le o iai ni togafitiga faʻapitoa mo togafitiga. Faʻaliga; Naʻo le vaega 2 (Head & Neck SCC) ma le kulupu 3 (Isi SCC) o loʻo tatala nei
Nofoaga: 11 nofoaga
Suesuega Immuno-togafitiga Suesuega e suʻesuʻe ai le Saogalēmū ma le aoga o Nivolumab, ma Nivolumab Combination Therapy i Virus-fesoʻotaʻiga Tumors
O le mafuaʻaga o lenei suʻesuʻega e suʻesuʻe ai le saogalemu ma le aoga o le nivolumab, ma le nivolumab tuufaatasi togafitiga, e togafitia ai tagata mamaʻi o loʻo i ai siama e fesoʻotaʻi ma siama. O nisi siama ua lauiloa e faia se sao i tumo fausiaina ma le tuputupu ae. O lenei suʻesuʻega o le a suʻesuʻeina ai aʻafiaga o vailaʻau suʻesuʻe, i tagata mamaʻi o loʻo i ai ituaiga ituaiga o tuma nei - ituaiga kanesa - Merkel Cell Cancer - Kanesa kanesa-E le toe lesitalaina lenei ituaiga tuma - Vaʻaiga ma kanesa feula-E le toe lesitalaina lenei ituaiga tuma - Kanesa kanesa - E le toe lesitalaina lenei ituaiga tuma - Ao ma le Kanesa Kanesa - Le toe lesitalaina nei ituaiga tuma
Nofoaga: 10 nofoaga
Pembrolizumab Versus Placebo I le maeʻa ai o taʻotoga ma le susulu atu o tagata i tagata o loʻo auai ma le siʻosiʻomia o le sela o le siʻosiʻi o le tino o le siʻosiʻomaga (MK-3475-630 / KEYNOTE-630)
Lenei o se randomized, faʻalua-tauaso, suʻesuʻega e faʻatusatusa ai le pembrolizumab ma le placebo na tuʻuina atu e avea ma fesoasoani togafitiga i tagata auai ma le sili atu le lamatiaga o loʻo maua i le lotoifale cutaneous squamous cell carcinoma (LA cSCC) na faia se taʻotoga ma togafiti faʻamoemoe faʻatasi ma le radiotherapy. O le manatu muamua e faʻapea o le pembrolizumab e sili atu i le placebo i le faʻateleina o le toe ola saoloto (RFS).
Nofoaga: 10 nofoaga
Lenei Suʻesuʻega Iloilo le KRT-232, o le Novel Oral Small Molecule Inhibitor o le MDM2, mo le togafitia o tagata mamaʻi ma (p53WT) Merkel Cell Carcinoma O e ua le mafai Anti-PD-1 / PD-L1 Immunotherapy
O lenei suʻesuʻega e iloilo ai le KRT-232, o se tala tuʻi laititi mole faʻatamaina o le MDM2, mo le togafitia o tagata mamaʻi ma Merkel Cell Carcinoma (MCC) ua le manuia togafitiga ma le sili atu tasi anti-PD-1 poʻo anti-PD-L1 immunotherapy. O le taofiofia ole MDM2 ose tala fou lea o gaioiga i le MCC. O lenei suʻesuʻega o le Vaega 2, Open-Label, Nofofua-Lima Suʻesuʻega o le KRT-232 i Tagata mamaʻi ma le p53 Wild-Type (p53WT) Merkel Cell Carcinoma
Nofoaga: 11 nofoaga
O le suʻesuʻeina o le XmAb®23104 i mataupu e iai fofoa alualu i luma filifilia (DUET-3)
Lenei o le Vaega 1, tele fualaʻau, alu i luga fualaʻau faʻateleina suʻesuʻega e faʻamatalaina le MTD / RD ma tulafono a le XmAb23104, e faʻamatalaina le saogalemu ma le faʻapalepaleina, e iloilo ai PK ma le puipuia o le tino, ma muamua iloiloina anti-tumo gaioiga o XmAb23104 i mataupu ma filifilia alualu i luma tuma.
Nofoaga: 9 nofoaga
Adjuvant Avelumab i le Merkel Cell Kanesa
O lenei randomized phase III faʻataʻitaʻiga suʻesuʻega pe faʻafefea ona aoga avelumab i le togafitia o tagata mamaʻi ma Merkel cell kanesa ua sosolo atu i le lymph nodes ma sa faia se taotoga ma pe leai radiation togafitiga. Monoclonal antibodies, pei o le avelumab, e ono faʻaosofia ai le puipuiga o le tino ma faʻalavelave ai i le mafai o sela tuma e tutupu ma sosolo.
Nofoaga: 10 nofoaga
QUILT-3.055: O se Suesueina o le ALT-803 i le Tuʻufaʻatasia ma le PD-1 / PD-L1 Checkpoint Inhibitor i tagata mamaʻi ma kanesa maualuga.
Lenei o le Vaega IIb, tasi-lima, multicohort, tatala-igoa multicenter suʻesuʻega o le ALT-803 faʻatasi ai ma le FDA-faʻamaonia PD-1 / PD-L1 siaki siaki taofi i tagata mamaʻi ma alualu i luma kanesa ua alualu i luma mulimuli ane i le amataga tali i togafitiga ma le PD-1 / PD-L1 siaki auala e taofi ai le auala. O gasegase uma o le a mauaina le tuʻufaʻatasiga togafitiga o PD-1 / PD-L1 siaki siaki faʻatasi ai ma le ALT-803 e oʻo atu i le 16 taʻamilosaga. Taamilosaga taʻitasi e ono vaiaso le umi. Uma gasegase o le a mauaina ALT-803 tasi i le 3 vaiaso. O tagata gasegase o le a mauaina foi le tutusa siaki siaki na latou mauaina i le taimi o latou togafitiga muamua. Radiologic iloiloina o le a tupu i le faaiuga o taʻamilosaga taʻamilosaga taʻitasi. Togafitiga o le a faʻaauau pea e oʻo atu i le 2 tausaga, pe seʻi vagana ua maua e le tagata maʻi faʻamaonia alualu i luma faʻamaʻi poʻo le taliaina oona, faʻateʻaina maliega, pe afai e lagona e le Tagata suʻesuʻe ua le o toe i le lelei a le tagata maʻi ona faʻaauau togafitiga. Tagata mamaʻi o le a mulimulitaʻia mo faʻamaʻi alualu i luma, post-therapies, ma le ola e ala i le 24 masina talu ai pulega o le muamua fualaʻau o suʻesuʻega vailaʻau.
Nofoaga: 9 nofoaga
Saogalēmū, Faʻapalepale, Immunogenicity, ma Antitumor Gaoioiga o GEN-009 Adjuvanted Vaccine
I lenei suʻesuʻega, o loʻo iloiloina ai e Genocea se tisaini suʻesuʻe, faʻapitoa i tui puipuia, GEN-009, o loʻo atiaʻeina mo le togafitia o tagata mamaʻi ua iai ni tuma tuma. O se mea faigaluega talafeagai na fausia e Genocea, ua faʻaigoaina o le ATLAS ™ (Antigen Lead Acqu acquisition System) o le a faʻaaogaina e faʻailoa ai neoantigens i tumo uma o le tagata maʻi ua iloa e latou CD4 ma / poʻo CD8 T sela. ATLAS-faʻailoa neoantigens o le a tuʻufaʻatasia i totonu o le tagata maʻi tui faʻapitoa i le tulaga o gaosia umi peptides (SLPs).
Nofoaga: 9 nofoaga
O se suʻesuʻega o le NKTR-262 i le tuʻufaʻatasia ma le NKTR-214 ma le NKTR-214 Plus Nivolumab i tagata mamaʻi ma faʻaletonu i luga ole laʻau tutoʻi.
Tagata mamaʻi o le a mauaina intra-tumoral (IT) NKTR-262 i le 3-vaiaso togafitiga taʻamilosaga. I le taimi o le vaega 1 fualaʻau faʻateleina vaega o le faʻamasinoga, NKTR-262 o le a tuʻufaʻatasia ma faʻatonutonuina faiga o bempegaldesleukin. A maeʻa ona fuafuaina le tuʻufaʻatasia Vaega fautuaina 2 (RP2D) o le NKTR-262, i le va o le 6 ma le 12 tagata mamaʻi e mafai ona lesitalaina i le RP2D e faʻamalamalama atili ai le saogalemu ma le faʻapalepale faʻamatalaga o le tuʻufaʻatasia o le NKTR 262 ma le bempegaldesleukin (faʻalua) poʻo le NKTR 262 faʻaopoopo. bempegaldesleukin faatasi ai ma le nivolumab (tolu tolu) i Cohorts A ma le B, faʻatulagaina. I le vaega 2 fualaʻau faʻalauteleina vaega, tagata gasegase o le a togafitia i le faaluaina poʻo le tolu tolu i le toe faʻafouina / refactory faʻatulagaina ma muamua laina o togafitiga.
Nofoaga: 14 nofoaga
O se faʻataʻitaʻiga le masani ai o le Pembrolizumab & Radiotherapy o loʻo tupu i le Radiotherapy i le High-Risk Soft Tissue Sarcoma o le ogaoga.
Lenei o se matala-igoa, tele-faʻalapotopotoga vaega II randomized suʻesuʻega faʻatusatusaina neoadjuvant radiotherapy mulimuli ai ma taotoga resection i neoadjuvant pembrolizumab ma le tutusa radiotherapy, sosoo ai ma taotoga resection ma adjuvant pembrolizumab. Le aofaʻi umi o le pembrolizumab o le a tasi le tausaga i le faʻataʻitaʻiga lima.
Nofoaga: 10 nofoaga
Proton Beam poʻo le Photon-Base Intensity-Modulated Radiation Therapy i le togafitia o tagata mamaʻi ma le kanesa o le Salivary Gland, Kanesa kanesa, poʻo le Melanoma
O lenei faʻataʻitaʻiga vaega II faʻataʻitaʻiga suʻesuʻeina le itu aʻafiaga o le proton beam poʻo le photon-based intensity-modulated radiation therapy i le togafitia o tagata mamaʻi ma le kanesa o le masii, kanesa o le paʻu, poʻo le melanoma. Proton beam radiation therapy faʻaaogaina o tamaʻi totoga o vaega e tuʻuina atu faʻasasaʻo tuusaʻo i le tumo ma ono mafua ai laititi le faʻaleagaina o masani tino. Faʻamalosi-faʻaaogaina poʻo le faʻasologa o fasimea o le faʻasologa o fasimea e faʻaalu ai malosiʻaga maualuga ave-x-ave e faʻataʻitaʻia ai le tuma ma ono faʻaititia ai foʻi le leaga o le tino. E leʻo iloa pe a faʻapea o le proton beam radiation therapy e sili atu lona aoga nai lo le photon-based intensity-modulated radiation therapy i le togafitia o tagata mamaʻi ua iai le kanesa o le galu, kanesa o le paʻu, poʻo le melanoma.
Nofoaga: 8 nofoaga
O le paʻu faʻaeletise o le paʻu o le Brachytherapy i le togafitia o tagata matutua o loʻo maua i le maʻi fou o le Basal Cell poʻo le Squamous Cell Paʻu Kanesa
O lenei pailate faʻataʻitaʻi faʻataʻitaʻi suʻesuʻe suʻesuʻe pe faʻafefea ona aoga eletise paʻu luga brachytherapy (ESSB) i le togafitia o tagata matutua tagata mamaʻi faʻatoa maua i le amataga o le basal cell poʻo le squamous cell paʻu kanesa. ESSB o se ituaiga o faʻamalositino togafitiga e faʻaaogaina paʻu luga applicators e tuu eletise eletise mafuaʻaga e togafitia paʻu kanesa. O tagata e suʻeina le paʻu i luga e lapotopoto, o tisiketi lamolemole e faapipii i le masini togafitiga o le radiation, ma aveese le paʻu mo togafitiga. ESSB mafai faʻatagaina le tumo e togafitia a o faʻavae tino soifua maloloina e le afaina i le radiation.
Nofoaga: 8 nofoaga
Stereotactic Body Radiation Therapy i le togafitia o tagata mamaʻi ma Metastatic Kanesa ma le faʻatapulaʻaina o le alualu i luma i Immune Checkpoint Inhibitors
Lenei vaega II suʻesuʻega suʻesuʻe pe o le a le lelei o le stereotactic body radiation therapy e galue ai i le togafitia o tagata mamaʻi ma le kanesa ua salalau atu i isi nofoaga i le tino ma le faʻatapulaʻaina o le alualu i luma aʻo puipuia le siaki siaki puipuia. O le Stereotactic body radiation therapy e faʻaaoga ai meafaigaluega faʻapitoa e faʻatulagaina ai se tagata maʻi ma tuʻuina atu le radiation i tumors ma le maualuga atoatoa. Lenei metotia mafai fasiotia fasiotia sela sela ma le itiiti ifo tui i luga o se puʻupuʻu vaitaimi ma mafua ai laʻititi faʻaleagaina o masani aano.
Nofoaga: 7 nofoaga
Cabozantinib S-malate ma Cetuximab i le togafitia o tagata mamaʻi ma Metastatic Head ma ua o le Cell Squamous Cell
Lenei vaega I suʻesuʻega suesueina le itu aafiaga ma sili ona lelei tui o cabozantinib S-malate ma pe a tuuina atu ma cetuximab i le togafitia o gasegase ma le ulu ma le ua squamous sela kanesa ua salalau atu i isi nofoaga i le tino. Cabozantinib S-malate ono faʻatelegeseina le tuputupu aʻe o sela kanesa i le tipi ese o le toto sapalai e manaʻomia e le kanesa e ola ma tuputupu aʻe. Immunotherapy ma monoclonal antibodies, e pei o le cetuximab, e ono faʻatupuina suiga i le tino o le tino ma mafai ai ona faʻalavelave i le mafai o tumo sela e tutupu ma sosolo. Le foaʻiina ole cabozantinib S-malate ma cetuximab atonu e aoga tele ile togafitia o tagata mamaʻi ile kanesa ole ulu ma le ua.
Nofoaga: 7 nofoaga
Saogalēmū, Faʻataʻitaʻiga Lelei ma PK o Isatuximab (SAR650984) Tuʻufaʻatasi poʻo i le Tuʻufaʻatasia ma Atezolizumab i Tagata Maʻi Ma Le Maualuga Malignancies
Sini Autu: - Vaega1: Ia faʻamatalaina le saogalemu ma le faʻapalepaleina o le isatuximab faʻatasi ma le atezolizumab i tagata o loʻo auai ma le hepatocellular carcinoma (HCC), o le platinum-refactory recurrent / metastatic squamous cell carcinoma o le ulu ma le ua (SCCHN), platinum-resistant / kanesa o le ovarian epithelial ovarian kanesa (EOC), poʻo glioblastoma multiforme faifai pea (GBM), ma ia fuafuaina le fautuaina Phase 2 fualaʻau (RP2D). - Vaega2: E iloilo ai tali fua (RR) o isatuximab faʻatasi ma atezolizumab i tagata auai ma HCC poʻo SCCHN poʻo EOC. - Vaega 2: Ia iloiloina le alualu i luma saoloto ola fua faatatau i 6 masina (PFS-6) o isatuximab faatasi ma atezolizumab, po o se tasi sui sooupu i tagata auai ma GBM. Sini Aoga Lona Lua: - Ia iloilo le saogalemu talaaga o isatuximab monotherapy (naʻo GBM), poʻo le tuʻufaʻatasia ma atezolizumab i le Vaega 2. - Le iloiloina o le puipuiga o le isatuximab ma le atezolizumab. - Faʻailogaina le igoa o le igoa o le isatuximab nofofua (GBM) ma le atezolizumab faʻatasi ai ma le isatuximab. - Ia iloilo le aoga atoa o le isatuximab faʻatasi ma le atezolizumab, poʻo le sui e toʻatasi (naʻo le GBM).
Nofoaga: 7 nofoaga
O se Suesuega o le INCMGA00012 i le Metastatic Merkel Cell Carcinoma (POD1UM-201)
O le mafuaʻaga o lenei suʻesuʻega o le iloiloina o le falemaʻi gaioiga ma le saogalemu o INCMGA00012 i tagata auai ma alualu i luma / metastatic Merkel sela kanesa (MCC).
Nofoaga: 8 nofoaga
Lenvatinib Mesylate ma Cetuximab i le togafitia o tagata mamaʻi ma le toe faʻasolosolo poʻo le Metastatic Head ma ua o le Squamous Cell Carcinoma poʻo le Cutaneous Squamous Cell Carcinoma
Lenei vaega I / Ib suʻesuʻega suʻesuʻega le sili lelei fualaʻau ma aʻafiaga o lenvatinib mesylate ma cetuximab i le togafitia o tagata mamaʻi ma le ulu ma le ua o le sela sela o le sela o le sela o le sela ua toe foʻi mai (toe tupu) pe salalau i isi nofoaga i le tino (metastatic ). Lenvatinib mesylate mafai ona taofi le tuputupu aʻe o sela tuma i le polokaina o nisi o enzymes manaʻomia mo sela tuputupu aʻe. Monoclonal antodies, pei o le cetuximab, e ono faʻalavelave ile gafatia ole tumo sela ona tutupu ma sosolo. O le tuʻuina atu o le lenvatinib mesylate ma le cetuximab atonu e sili atu lona aoga i le togafitia o tagata mamaʻi e iai le ulu ma le ua o le sela sela poʻo le tino o le sela sela o le sela.
Nofoaga: 7 nofoaga
PEN-221 i le Somatostatin Receptor 2 Faʻamatalaina Advanced kanesa aofia ai Neuroendocrine ma tamai sela sela sela Protocol PEN-221-001 o se tatala-igoa, multicenter Vaega 1 / 2a suʻesuʻe iloilo PEN-221 i tagata mamaʻi ma SSTR2 faʻaalia gastroenteropancreatic maualuga (GEP) poʻo māmā poʻo thymus poʻo isi neuroendocrine tumors poʻo tamaʻi sela kanesa kanesa poʻo tele sela neuroendocrine kanesa o le māmā.
Nofoaga: 7 nofoaga
1 2 3 4 5 Le isi> National Cancer Institute
